Nuvectis Pharma, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 18.57 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 605.04M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Details
| Name | Nuvectis Pharma, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 16 |
| Founded | 2020 |
| Ipo Date | 2022-02-04 |
| Ceo | Ron Bentsur |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 5.00 |
| Isin | US67080T1088 |
| Cusip | 67080T108 |
| Cik | 1875558 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Ron Bentsur M.B.A. | Co-Founder, Chairman, Chief Executive Officer and President |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive Vice President, Chief Scientific and Business Officer |
| Shay Shemesh | Co-Founder, Executive Vice President, Chief Development and Operations Officer |
| Michael Carson CPA | Vice President of Finance |
Contact
| Address | 1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, New Jersey 07024, United States |
| Phone | 201 614 3150 |
| Website | https://www.nuvectis.com |